公开(公告)号：US20200079866A1

公开(公告)日：2020-03-12

申请号：US16582534

申请日：2019-09-25

Applicant: BIONTECH SE ,  GENMAB A/S

Inventor： Ugur Sahin ,  Friederike Gieseke ,  Isil Altintas ,  David Satijn ,  Paul Parren

IPC: C07K16/28

Abstract: The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. The present invention further relates to nucleic acid molecules encoding such binding agents, to cells comprising such nucleic acid molecules and to pharmaceutical compositions and kits.

公开(公告)号：US10544220B2

公开(公告)日：2020-01-28

申请号：US15541594

申请日：2016-01-08

Applicant: GENMAB A/S

Inventor： Patrick Engelberts ,  Esther Breij ,  Rik Rademaker ,  Isil Altintas ,  David Satijn ,  Sandra Verploegen ,  Riemke Van Dijkhuizen Radersma ,  Edward Van Den Brink ,  Janine Schuurman ,  Paul Parren

IPC: C07K16/28 ,  C07K16/30 ,  A61K39/395 ,  A61K39/00

Abstract: Bispecific antibodies directed to CD3 and CD20 and uses of such bispecific antibodies, in particular use thereof in the treatment of diseases in which specific targeting and T cell-mediated killing of cells that express CD20 is desired.

公开(公告)号：US20190352423A1

公开(公告)日：2019-11-21

申请号：US16072437

申请日：2017-02-03

Applicant: GENMAB A/S

Inventor： Bart DE GOEIJ ,  Joost MELIS ,  Tom VINK ,  Hendrik TEN NAPEL ,  Esther BREIJ ,  David SATIJN ,  Paul PARREN

IPC: C07K16/32 ,  C07K16/28 ,  A61K47/68 ,  A61P35/00

Abstract: The present invention relates to a multispecific antigen-binding molecule comprising a first antigen-binding domain and a second antigen-binding domain. The first domain specifically binds a target molecule (T), and the second domain specifically binds an internalizing effector protein (E), the second antigen-binding domain having a dissociation constant (KD) with E of between 10−9 and 10−8 M. The multispecific antigen-binding molecule is useful in a method for treating and/or preventing a cancer.

公开(公告)号：US20190315880A1

公开(公告)日：2019-10-17

申请号：US16367933

申请日：2019-03-28

Applicant: GENMAB A/S

Inventor： David SATIJN ,  Sandra VERPLOEGEN ,  Wim BLEEKER ,  Steen LISBY ,  Jan VAN DE WINKEL ,  Patrick VAN BERKEL ,  Paul PARREN

IPC: C07K16/30 ,  A61K47/68 ,  C07K16/36 ,  A61K45/06

Abstract: Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapeutic and diagnostic methods for using the antibodies and antibody drug conjugates.

公开(公告)号：US20190233522A1

公开(公告)日：2019-08-01

申请号：US16316000

申请日：2017-07-07

Applicant: GENMAB A/S

Inventor： Ulf FORSSMANN ,  Steen LISBY ,  Nedjad LOSIC

IPC: C07K16/28 ,  A61K47/68 ,  A61P35/00

CPC classification number: C07K16/2863 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6851 ,  A61K2039/505 ,  A61P35/00 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/732 ,  C07K2317/77 ,  C07K2317/92

Abstract: An antibody-drug conjugate (ADC) based on an antibody binding to human AXL and pharmaceutical compositions comprising the ADC for use in the treatment of a cancer comprising administering to a subject a weekly dose of from about 0.45 mg/kg to about 2.0 mg/kg of the ADC once a week for three consecutive weeks followed by a one week resting period without any administration of the ADC so that each cycle time is 28 days including the resting period.

公开(公告)号：US10351629B2

公开(公告)日：2019-07-16

申请号：US15072983

申请日：2016-03-17

Applicant: GENMAB A/S

Inventor： Janine Schuurman ,  Tom Vink ,  Jan Van De Winkel ,  Aran Frank Labrijn ,  Paul Parren ,  Willem Karel Bleeker ,  Frank Beurskens ,  Patrick Van Berkel

IPC: C07K16/00 ,  A61K39/00 ,  C12N15/85 ,  C07K16/28

Abstract: The invention relates to novel non-human transgenic animals, which upon antigenic stimulation are capable of producing monovalent antibodies binding to a selected antigen, modified heavy chain transgenes, methods for producing the non-human transgenic animals, methods for immunizing the non-human transgenic animals for as well as monovalent antibodies obtainable by such immunization methods.

公开(公告)号：US20190169298A1

公开(公告)日：2019-06-06

申请号：US16183300

申请日：2018-11-07

Applicant: GENMAB A/S

Inventor： Paul PARREN ,  Janine SCHUURMAN ,  Tom VINK ,  Willem Karel BLEEKER ,  Jan VAN DE WINKEL ,  Patrick VAN BERKEL ,  Frank BEURSKENS

IPC: C07K16/28

Abstract: The present invention provides monovalent antibodies with a long half-life when administered in vivo, methods of making such monovalent antibodies, pharmaceutical compositions comprising such antibodies, and uses of the monovalent antibodies.

公开(公告)号：US20190160170A1

公开(公告)日：2019-05-30

申请号：US16270317

申请日：2019-02-07

Applicant: GENMAB A/S

Inventor： Esther Breij ,  David Satijn ,  Edward Norbert Van Den Brink ,  Dennis Verzijl ,  Rob N. De Jong ,  Paul Parren ,  Riemke Van Dijkhuizen Radersma

IPC: A61K39/395 ,  C07K16/28 ,  A61K47/68 ,  C07K16/30

Abstract: The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.

公开(公告)号：US20190030180A1

公开(公告)日：2019-01-31

申请号：US16069391

申请日：2017-01-13

Applicant: GENMAB A/S

Inventor： Lene Schantz HARLOW ,  Timothy Warren PAUL ,  Brendan M. MAYHUGH ,  Kelly Ann ROBY ,  Gregory Allan SACHA ,  Xiaona JING ,  Andrew HAGARMAN ,  Cale HALBLEIB

IPC: A61K47/68 ,  A61K9/19 ,  C07K16/28 ,  A61K38/07 ,  A61K47/18 ,  A61K47/26

Abstract: Disclosed herein are surfactant free antibody and antibody-drug-conjugate (ADC) formulations for anti-AXL antibodies and ADCs, including aqueous formulations, lyophilized formulations, and reconstituted formulations, as well as related processes and uses. The formulations are particularly suitable for an anti-AXL ADC based on an auristatin or DM1 derivative or other similarly hydrophobic drugs. Some formulations comprise histidine and mannitol.

公开(公告)号：US20180022816A1

公开(公告)日：2018-01-25

申请号：US15627921

申请日：2017-06-20

Applicant: GENMAB A/S

Inventor： Bart DE GOEIJ ,  Edward N. VAN DEN BRINK ,  Simone DE HAIJ ,  Thilo RIEDL ,  Rene HOET ,  Ole BAADSGAARD, D.M.Sc. ,  David SATIJN ,  Jan VAN DE WINKEL ,  Paul PARREN

IPC: C07K16/30 ,  C07K16/32 ,  A61K39/00

Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.